CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

Written by Customer Service on January 8, 2023. Posted in Public Companies.

Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (“CymaBay” or the “Company”) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis (“PBC”). Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market seladelpar in Japan for PBC. Kaken will make an upfront payment to CymaBay of ¥4.5 billion (approximately $34.0 million at...

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Written by Customer Service on January 8, 2023. Posted in Public Companies.

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of...

Merus Provides 2023 Outlook

Written by Customer Service on January 8, 2023. Posted in Public Companies.

– As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy – Petosemtamab clinical update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023 – Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities, expected to fund Merus’ operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook. “2023 looks to be another productive year for Merus with multiple value-creating...

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

Written by Customer Service on January 8, 2023. Posted in Public Companies.

– Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – – Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis responders, 56% were overall responders, 67% achieved a Clinical Activity Score (CAS) of 0 or 1, and 20% had complete resolution of their diplopia – – Across all 21 VRDN-001 treated patients to date, 71% were proptosis responders, 67% were overall responders, 62% achieved a CAS of 0 or 1, and 54% had complete resolution of their diplopia, with a favorable safety profile seen across all dose levels – – 3 mg/kg data support planned once-monthly low-volume subcutaneous dosing profile for VRDN-002 and VRDN-003 – WALTHAM, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ:...

Aims to enhance OT exposure detection capability by identifying misconfigured connected devices Seeks to improve overall security of customers and partners in the OT environment

Written by Customer Service on January 8, 2023. Posted in Public Companies.

Schneider Electric and BitSight announcement.jpg.jpg Schneider Electric and BitSight announcement.jpg.jpg Schneider Electric, the global leader in the digital transformation of energy management and automation, and BitSight, the leader in detecting and managing cyber risk, today announced a strategic partnership to develop a first-of-its-kind global Operational Technology (OT) Risk Identification and Threat Intelligence capability. In recent years, both opportunistic and advanced cyber threat actors have shown increased willingness to target industrial and operational sites. Schneider Electric and BitSight each see their partnership as an important step in furthering their commitment to improve the security and resilience of their communities - by detecting OT protocols exposed over the internet and contextualizing them with improved...

Day: January 8, 2023